Mixture Cure Model Projects 87% of Myeloma Patients on Tec-Dara May Achieve Normal Life Expectancy

On September 23, 2026, Johnson & Johnson released statistical modeling data from the Phase 3 MajesTEC-3 trial projecting that approximately 87% of patients treated with a combination of Tecvayli and Darzalex Faspro may achieve a life expectancy comparable to the general population. The analysis applied a relative survival mixture cure model to clinical outcomes for patients with relapsed or refractory multiple myeloma who had received one to three prior lines of therapy.[2][3]

Multiple myeloma is the second most common blood cancer, characterized by the malignant proliferation of plasma cells in the bone marrow. For patients whose disease has relapsed or become refractory to initial treatments, subsequent lines of therapy historically offer diminishing returns, making the search for regimens that provide durable, long-term disease control a primary focus of oncological research.[1][3]

The mixture cure model is a statistical approach that estimates the proportion of patients—the "cure fraction"—who will not experience excess mortality from their disease compared to an age-matched general population. By applying this model to actual progression-free survival and overall survival data from the trial, researchers estimated an 86.6% cure fraction for the Tecvayli and Darzalex Faspro (Tec-Dara) combination, compared to 0% for the standard-of-care comparator arm.[2][4]

The model projected a remaining life expectancy of 18.5 years for patients receiving the Tec-Dara combination. This figure is nearly four times the 4.9 years projected for patients receiving the standard-of-care regimen—dexamethasone with either pomalidomide or bortezomib (DPd/DVd)—and approaches the 21.1 years expected for the matched general population.[1][2]

These projections are anchored by substantial clinical improvements observed at the 36-month mark of the MajesTEC-3 study. The cumulative incidence of disease progression was 8.7% for the Tec-Dara arm versus 62.1% for the standard-of-care arm, representing a 90% reduction in the risk of progression.[2][3]

Overall survival at 36 months stood at 83.3% for patients treated with the combination, compared to 65.0% for those on the standard regimen. Notably, the data showed no significant difference in non-relapse mortality between the two groups, with rates at 10.2% and 9.0% respectively, indicating that the survival benefit was driven entirely by improved disease control rather than a shift in other mortality risks.[1][2]

"These findings underscore how consequential treatment choice at first relapse can be in shaping a patient's long-term trajectory," said Dr. Luciano J. Costa, director of the Multiple Myeloma Research and Treatment Program at the University of Alabama at Birmingham. He noted that the sustained disease control observed with the combination is changing expectations for what treatment can achieve in relapsed or refractory multiple myeloma.[1]

The combination regimen received approval from the U.S. Food and Drug Administration in March 2026 and the European Commission in August 2026 for use as early as the second line of therapy. As these statistical models are presented to the International Myeloma Society, the focus will shift to how quickly clinical guidelines and real-world prescribing practices adapt to the projected long-term survival benefits.[1][3]